Gland Pharma Limited
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model…
What Gland files
- Others76
- Investor Meet74
- Important27
- Updates23
- Board Meeting11
- PPTs6
Gland Pharma's VSEZ Sterile Oncology Formulations & API Facilities in Visakhapatnam successfully cleared a USFDA Good Manufacturing Practice (GMP) inspection, concluding with zero (0) Form 483 observations. This is a positive operational development.
Gland Pharma delivered record Q1FY27 revenue of ₹1,800.3 Cr (+20% YoY) and PAT of ₹317 Cr (+47% YoY). Growth driven by successful CDMO strategy, new product launches, and robust B2B demand. Strong pipeline and new partnerships underpin future expansion.
Gland Pharma sealed a strategic CDMO partnership with a global firm for sterile injectables. This agreement covers 55 SKUs, targeting USD 90-100 million in annual revenue from 2029, significantly boosting long-term business visibility.
Gland Pharma partnered with Neuland Labs for sterile API manufacturing, expanding capacity by ~1400 kg annually at its Visakhapatnam facility. This strategic collaboration strengthens Gland's sterile API manufacturing capabilities to meet growing global demand.
Gland Pharma received USFDA approval for Sugammadex Injection and launched it immediately. This product targets a US market with annual sales of approximately USD 1.6 billion.